Accessibility Menu
Amgen logo

Amgen(NASDAQ) AMGN

Current Price$365.34
Market Cap$196.55BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (1983)+385,661%
5 Year+74%
1 Year+27%
1 Month+8%
Amgen last closing stock price
MetricPriceDate
Last closeUSD 364.172026-07-20
Amgen stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+1.03%USD 360.452026-07-13
1 month+7.87%USD 337.602026-06-18
3 month+6.4%USD 342.282026-04-21
Year to date+12.88%USD 322.622025-12-31
1 year+27.26%USD 286.162025-07-18
3 year+70.05%USD 214.152023-07-21
5 year+74.09%USD 209.182021-07-21
Since inception+385,661.03%USD 0.091983-12-20

Amgen Financials at a Glance

Market Cap

$196.55BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$37.24B

Net Income (TTM)

$7.80B

EPS (TTM)

$14.38

P/E Ratio

25.33

Dividend

$9.80

Beta (Volatility)

0.44 (Low)

Price

$365.34

Volume

72,194

Open

$365.09

Previous Close

$364.17

Daily Range

$362.27 - $368.69

52-Week Range

$269.77 - $391.29

Estimated Earnings Date

Aug 4, 2026

AMGN: Motley Fool Moneyball Superscore

79

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Amgen

Amgen makes medicines for people with serious health conditions. Its products help treat cancer, arthritis, and bone loss. These medicines support patients, doctors, and hospitals worldwide.

What’s in the Amgen Medicine Cabinet?

  • Inflammation Treatments: Enbrel and Otezla help manage arthritis and skin conditions; 17% of 2024 revenue.
  • Cancer and Blood Disorders: Neulasta, KYPROLIS, and BLINCYTO support cancer patients; 10% of 2024 revenue.
  • Bone Health: Prolia and XGEVA treat osteoporosis and bone complications; 21% of 2024 revenue.
  • Cardiovascular Care: Repatha lowers cholesterol and heart risk; 7% of 2024 revenue.

Growth Moves: Amgen’s Expansion Playbook

  • Acquired Horizon Therapeutics in 2023, adding rare disease drugs.
  • Launched new products like IMDELLTRA (2024) and expanded BLINCYTO use (2024).
  • Opened new manufacturing plants in Ohio (2024) and North Carolina (2025).
  • Formed partnerships with AstraZeneca, UCB, and BeiGene to boost research and global reach.
  • Entered Japan with TEPEZZA in 2024 and expanded in Asia-Pacific markets.

What Makes Amgen Stand Out?

Amgen operates in about 100 countries, reaching patients globally. Its in-house research and manufacturing allow quick product launches and supply chain control. The company’s mix of original drugs and biosimilars helps it adapt to changing markets.

Five Things You Need to Know

  • Revenue was $33.42 billion in 2024, up 19% from 2023.
  • U.S. sales made up 73% of product revenue in 2024.
  • Net income was $4.09 billion in 2024, down 39% from 2023.
  • R&D spending was $5.96 billion in 2024, up 25% from 2023.
  • Three wholesalers handled 77% of global sales in 2024.

Bottom Line

Amgen has grown through new drugs, acquisitions, and global expansion. Its broad product mix and strong research base help it adapt in a changing healthcare market.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Employees

31,500

CEO

Robert A. Bradway, MBA

Headquarters

Thousand Oaks, CA 91320-1799, US

AMGN Financials

Key Financial Metrics (TTM)

Gross Margin

71.46%

Operating Margin

31.63%

Net Income Margin

20.95%

Return on Equity

89.41%

Return on Capital

16.88%

Return on Assets

8.43%

Earnings Yield

3.95%

Dividend Yield

2.69%

Payout Ratio

66.71%

Stock Overview

Market Cap

$196.55BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

539.71M

Volume

72.19K

Avg. Volume

2.69M

Financials (TTM)

Gross Profit

$26.61B

Operating Income

$11.78B

EBITDA

$16.69B

Operating Cash Flow

$10.76B

Capital Expenditure

-$2.16B

Free Cash Flow

$8.60B

Cash & ST Invst.

$12.04B

Total Debt

$57.32B

Amgen Performance Analysis

Amgen annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 26,092,000,0000.4%
20232023-12-31USD 28,010,000,0007.4%
20242024-12-31USD 33,232,000,00018.6%
20252025-12-31USD 36,741,000,00010.6%
Amgen sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3012.5%
Q32025-09-304.3%
Q42025-12-313.5%
Q12026-03-31-12.9%
Amgen annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD 12.1117.8%
20232023-12-31USD 12.493.1%
20242024-12-31USD 7.56-39.4%
20252025-12-31USD 14.2388.2%
Amgen sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-17.2%
Q32025-09-30123.8%
Q42025-12-31-58.7%
Q12026-03-3136.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$8.62B

+5.8%

Gross Profit

$5.87B

+13.4%

Gross Margin

68.16%

N/A

Market Cap

$196.55BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$6.24M

N/A

Employees

31,500

N/A

Net Income

$1.82B

+5.1%

EBITDA

$3.86B

-5.5%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$12.04B

+36.6%

Total Debt

$57.32B

-0.1%

Accounts Receivable

$9.14B

+12.4%

Inventory

$6.19B

-8.1%

Long Term Debt

$51.89B

-3.9%

Short Term Debt

$5.44B

+61.4%

Return on Assets

8.43%

N/A

Return on Invested Capital

17.44%

N/A

Free Cash Flow

$1.48B

+50.7%

Operating Cash Flow

$2.19B

+57.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
NVONovo Nordisk A/S
$49.27-0.69%
GILDGilead Sciences, Inc.
$130.19-2.27%
PFEPfizer Inc.
$24.91+0.63%
DHRDanaher Corporation
$178.69-11.15%

Trending Stocks

Symbol / CompanyPricePrice Chg
ONDSOndas
$7.59+0.10%
NOKNokia
$10.62+0.05%
AALAmerican Airlines Group
$15.19+0.00%
HLHecla Mining
$15.15+0.06%

Questions About AMGN

What is the current price of Amgen?

Amgen is trading at $365.39 per share.

What is the 52-week range for Amgen?

Over the past 52 weeks, Amgen has traded between $269.77 and $391.29.

How much debt does Amgen have?

As of the most recent reporting period, Amgen reported total debt of $57.32B.

How much cash does Amgen have on hand?

Amgen reported $12.04B in cash and cash equivalents in its most recent financial results.

What is Amgen’s dividend yield?

Amgen currently has a dividend yield of 2.69%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.